Denosumab-Induced Hypocalcemia in Cancer Patients

Denosumab is a monoclonal antibody that neutralises RANKL, suppressing osteoclast-mediated bone resorption in patients with skeletal metastases. In this population, hypocalcaemia emerges as a significant adverse event, with incidence influenced by tumour type, co-medications and baseline biochemical status. Severe serum calcium reductions may provoke neuromuscular irritability, cardiac dysrhythmias and interruptions of cancer therapy. Risk factors include extensive osteoblastic metastases, vitamin D deficiency, renal impairment and concomitant use of certain antacids or corticosteroids. Prevention and management rely on assessment and correction of calcium and vitamin D levels before treatment, regular monitoring during therapy and individualised supplementation protocols. A precise understanding of biochemical predictors and modifiable factors is essential to preserve both safety and efficacy.

Research from Nature Portfolio

A quantitative study employing ordered logistic regression in more than 300 advanced cancer patients defined key predictors of denosumab-induced hypocalcaemia despite prophylaxis. Concomitant administration of a proton pump inhibitor (vonoprazan) and a corticosteroid (dexamethasone) independently increased risk. Pre-treatment serum calcium ≤ 9.3 mg/dL, alkaline phosphatase ≥ 457 U/L and haemoglobin ≤ 10.4 g/dL were identified as optimal thresholds for stratifying susceptibility. Receiver operating characteristic analysis validated these cut-off values, offering a structured approach to personalise baseline assessment and prophylactic strategies.

Denosumab-Induced Hypocalcemia in Cancer Patients publication trend

The graph below shows the total number of articles in denosumab-induced hypocalcemia in cancer patients across all publications each year (not limited to Nature Index journals).

Technical terms

Denosumab: A fully human monoclonal antibody that binds RANKL, inhibiting osteoclast formation and bone resorption.

Hypocalcaemia: Abnormally low serum calcium concentration associated with neuromuscular and cardiac dysfunction.

RANKL: Receptor activator of nuclear factor κB ligand, a cytokine essential for osteoclast differentiation and activation.

Osteoclast: A specialised bone cell responsible for the resorption of mineralised bone matrix.

Alkaline phosphatase (ALP): An enzyme marker of bone formation and turnover, elevated in high osteoblastic activity.

References

1. Hypocalcaemia in patients with prostate cancer treated with a bisphosphonate or denosumab: prevention supports treatment completion. BMC Urology (2018).
2. Denosumab: mechanism of action and clinical outcomes. International Journal of Clinical Practice (2012).
3. Effect of denosumab versus zoledronic acid on calcium levels in cancer patients with bone metastasis: A retrospective cohort study. Journal of Oncology Pharmacy Practice (2019).
4. Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis. Scientific Reports (2021).
5. Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports. Journal of Medical Case Reports (2024).